CMS Cytotoxic Food Tests Coverage Policy — NCD 161 Update (2026)
TL;DR: The Centers for Medicare & Medicaid Services modified NCD 161 governing cytotoxic food tests, effective 2026-03-07. Cytotoxic leukocyte tests for food allergies have been excluded from Medicare coverage since August 5, 1985 — and that exclusion remains firmly in place.
If your billing team is fielding questions about cytotoxic food test billing under Medicare, this policy gives you a clear, unambiguous answer: these tests don't get covered. The CMS cytotoxic food tests coverage policy under NCD 161 has not softened over time. This update is a reaffirmation of the 1985 exclusion, not a new opening. Knowing that distinction saves your team from chasing reimbursement that will never arrive.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Cytotoxic Food Tests — NCD 161 |
| Policy Code | NCD 161 |
| Change Type | Modified |
| Effective Date | 2026-03-07 |
| Impact Level | Low — exclusion unchanged since 1985; update confirms existing non-coverage |
| Specialties Affected | Allergy, immunology, internal medicine, integrative medicine |
| Key Action | Flag cytotoxic leukocyte food allergy tests as non-covered in your charge capture and payer policy documentation |
CMS Cytotoxic Food Test Coverage Criteria and Medical Necessity Requirements 2026
NCD 161 is the National Coverage Determination governing Medicare coverage of cytotoxic food tests. It draws a hard line at August 5, 1985.
Before that date, Medicare covered cytotoxic food tests as an adjunct to in vivo clinical allergy tests in complex food allergy cases. After that date, coverage stopped entirely. The Centers for Medicare & Medicaid Services determined that available evidence does not show these tests are safe and effective.
That finding has not changed. The 2026 modification to NCD 161 does not introduce new medical necessity criteria because there are none to introduce. There is no covered indication, no clinical threshold that unlocks reimbursement, and no prior authorization pathway that changes the outcome. Cytotoxic leukocyte tests for food allergies are simply excluded.
This matters for your billing team because some providers — especially those practicing integrative or functional medicine — still order cytotoxic food panels. Patients sometimes present these orders alongside Medicare as their primary payer. Your team needs to catch that combination before a claim goes out.
The coverage policy is categorical. There is no room for medical necessity arguments on redetermination or appeal. If a claim goes out, a claim denial comes back.
CMS Cytotoxic Food Test Exclusions and Non-Covered Indications
The exclusion here is total and has been in effect since August 5, 1985. CMS published it as a formal ruling in the Federal Register on July 5, 1985 — before the effective date, giving providers advance notice. That ruling became the foundation of NCD 161.
Cytotoxic leukocyte tests for food allergies are excluded because the evidence does not support their clinical validity or safety. This is not a local coverage determination issue. It is not a Medicare Administrative Contractor call. The non-coverage applies nationally, across all MAC jurisdictions, with no exceptions.
Some practices confuse cytotoxic food tests with other allergy diagnostics that do carry Medicare coverage. Skin prick testing, intradermal testing, and IgE-based serology tests are separate services governed by separate policies. NCD 161 does not affect those. If your team bills for legitimate in vivo allergy testing, that work is not touched by this policy.
The real risk is when a provider orders a cytotoxic panel alongside covered allergy services. Your charge capture process needs to separate those two things cleanly. The covered services can bill. The cytotoxic test cannot.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Cytotoxic leukocyte tests for food allergies (post August 5, 1985) | Not Covered | No specific codes listed in NCD 161 | National exclusion; no prior authorization or appeal pathway applies |
| Cytotoxic food tests as adjunct to in vivo allergy tests (before August 5, 1985) | Not Covered (historical) | No specific codes listed in NCD 161 | Pre-1985 coverage is not applicable to current claims |
CMS Cytotoxic Food Test Billing Guidelines and Action Items 2026
The effective date of March 7, 2026 marks the formal modification of NCD 161. Here is what your billing team should do now.
| # | Action Item |
|---|---|
| 1 | Flag cytotoxic food tests as non-covered in your charge capture system. If your system does not already exclude these tests for Medicare patients, update it before you process any claims with a service date on or after March 7, 2026. The billing guidelines have not changed — but the policy modification is a good trigger for an internal audit. |
| 2 | Train front desk and clinical staff to identify cytotoxic food test orders from Medicare patients. The denial happens at the claim level, but the right place to stop it is before the service is rendered. If your clinical team knows these tests are excluded, they can counsel patients on financial responsibility before the appointment. |
| 3 | Issue an Advance Beneficiary Notice of Noncoverage (ABN) if the provider plans to order a cytotoxic food test for a Medicare patient. The ABN protects your practice and gives the patient informed choice. Without it, you cannot bill the patient for a non-covered service that was not disclosed in advance. |
| 4 | Review any open or pending claims that include cytotoxic food test charges billed to Medicare. If those claims went out without an ABN, you have limited options on recovery. Talk to your compliance officer before you decide how to handle outstanding balances. |
| 5 | Do not attempt prior authorization as a workaround. There is no prior authorization process that unlocks coverage for these tests. CMS has not created one. Submitting a prior auth request does not change the coverage policy and will not result in reimbursement. |
| 6 | Check your payer mix for Medicare Advantage plans. Medicare Advantage plans follow NCD 161 for mandatory exclusions. Confirm with each plan's billing guidelines whether cytotoxic food tests appear on their own non-covered services list or fall under the NCD by default. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cytotoxic Food Tests Under NCD 161
Covered CPT Codes
The NCD 161 policy does not list any covered CPT or HCPCS codes. There are no covered indications under this policy.
Not Covered — Cytotoxic Food Tests
NCD 161 does not specify particular CPT or HCPCS codes for cytotoxic leukocyte food allergy testing. CMS has not assigned a billable code set to this excluded service within this policy document.
If your billing team encounters codes associated with cytotoxic food testing — whether submitted by a lab or bundled into an allergy workup — verify the service description against the NCD 161 exclusion before billing Medicare. The absence of a specific code in the policy does not create a coverage opportunity. The categorical exclusion applies regardless of how the service is coded.
This is one area where you may want to loop in your compliance officer or billing consultant. If a lab partner is submitting cytotoxic food test results under a general lab code, your practice could be inadvertently passing along a non-covered charge to Medicare. That creates downstream claim denial risk and potential compliance exposure.
Key ICD-10-CM Diagnosis Codes
NCD 161 does not list specific ICD-10-CM diagnosis codes. The exclusion applies categorically to cytotoxic leukocyte tests for food allergies regardless of the diagnosis code on the claim.
Why This Policy Update Still Matters in 2026
You might look at a 1985 exclusion and wonder why CMS is touching it in 2026. That is a fair question.
Policy modifications like this one often happen for administrative reasons — formatting updates, cross-reference alignment, or system-level housekeeping in the NCD database. The substance of the coverage policy does not change. But the modification creates a new effective date, which means billing teams need to confirm their internal documentation reflects the current version.
The real issue here is not that anything changed. The issue is that billing teams sometimes treat a policy with a recent modification date as a signal that coverage criteria have shifted. With NCD 161, they have not. The August 5, 1985 exclusion is the policy. Everything else is administrative.
If your practice has been billing these tests — or if a provider in your group has been ordering them routinely — this is a good moment to stop and audit. A claim denial on a non-covered service is recoverable. A pattern of billing non-covered services without ABNs is a compliance issue.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.